Table 1. Resistance to first-line antituberculosis drugs among Mycobacterium tuberculosis complex isolates, Cubal, Angola, April 2014–July 2015* .
| Phenotypic drug susceptibility |
Isolates from new cases, n = 225 |
Isolates from retreatment cases, n = 83 |
|||
|---|---|---|---|---|---|
| No. |
% (95 CI) |
No. |
% (95 CI) |
||
| Susceptible to all 5 first-line drugs | 167 | 74.2 (68.1–79.5) | 14 | 16.9 (10.3–26.3) | |
| Resistance to any drug |
58 |
25.8 (20.5–31.9) |
|
69 |
83.1 (73.7–89.7) |
| Any resistance to the following | |||||
| INH | 47 | 20.9 (16.1–26.7) | 66 | 79.5 (69.6–86.8) | |
| RIF | 20 | 8.9 (5.8–13.3) | 61 | 73.5 (63.1–81.8) | |
| STM | 25 | 11.1 (7.6–15.9) | 42 | 50.6 (40.1–61.1) | |
| EMB | 10 | 4.4 (2.4–8.0) | 32 | 38.6 (28.8–49.3) | |
| PZA |
13 |
5.8 (3.4–9.6) |
|
37 |
44.6 (34.4–55.3) |
| Overall monodrug resistance | 31 | 13.8 (9.9–18.9) | 7 | 8.4 (4.1–16.4) | |
| INH only | 21 | 9.3 (6.2–13.8) | 4 | 4.8 (1.9–11.7) | |
| RIF only | 1 | 0.4 (0.1–2.5) | 2 | 2.4 (0.7–8.4) | |
| STM only | 8 | 3.6 (1.8–6.9) | 1 | 1.2 (0.2–6.5) | |
| PZA only |
1 |
0.4 (0.1–2.5) |
|
0 |
0.0 (0.0–4.4)† |
| Overall multidrug resistance | 18 | 8.0 (5.1–12.3) | 59 | 71.1 (60.6–79.7) | |
| INH + RIF | 4 | 1.8 (0.7–4.5) | 12 | 14.5 (8.5–23.6) | |
| INH + RIF + STM | 2 | 0.9 (0.2–3.2) | 5 | 6.0 (2.6–13.3) | |
| INH + RIF + EMB | 0 | 0.0 (0.0–1.7)† | 3 | 3.6 (1.2–10.1) | |
| INH + RIF + PZA | 2 | 0.9 (0.2–3.2) | 2 | 2.4 (0.7–8.4) | |
| INH + RIF + STM + EMB | 3 | 1.3 (0.5–3.8) | 4 | 4.8 (1.9–11.7) | |
| INH + RIF + STM + PZA | 1 | 0.4 (0.1–2.5) | 9 | 10.8 (5.8–19.3) | |
| INH + RIF + EMB + PZA | 1 | 0.4 (0.1–2.5) | 4 | 4.8 (1.9–11.7) | |
| INH + RIF + STM + EMB + PZA |
5 |
2.2 (1.0–5.1) |
|
20 |
24.1 (16.2–34.3) |
| Overall polydrug resistance | 9 | 4.0 (2.1–7.4) | 3 | 3.6 (1.2–10.1) | |
| INH + STM | 5 | 2.2 (1.0–5.1) | 0 | 0.0 (0.0–4.4)† | |
| INH + EMB | 1 | 0.4 (0.1–2.5) | 0 | 0.0 (0.0–4.4)† | |
| INH + PZA | 2 | 0.9 (0.2–3.2) | 0 | 0.0 (0.0–4.4)† | |
| INH + STM + EMB | 0 | 0.0 (0.0–1.7)† | 1 | 1.2 (0.2–6.5) | |
| INH + STM + PZA | 0 | 0.0 (0.0–1.7)† | 2 | 2.4 (0.7–8.4) | |
| RIF + STM + PZA | 1 | 0.4 (0.1–2.5) | 0 | 0.0 (0.0–4.4)† | |
*EMB, ethambutol; INH, isoniazid; PZA, pyrazinamide; RIF, rifampin; STM, streptomycin. †1-sided, 97.5% CI.